• We make platelets.

LEADING
THE WAY

As a science-driven company, Platelet BioGenesis has assembled a team comprising the world’s foremost experts in platelet and blood science.

Management

Headshot of Sam Rasty, PhD

SAM RASTY, PHD

President and Chief Executive Officer

Sam Rasty brings more than 20 years of experience in biopharma leadership in companies ranging from early-stage startups to global industry incumbents. Most recently, he served as chief operating officer at Homology Medicines, a leader in gene therapy and gene editing. Prior to Homology he was vice president and head of new products at the Rare Disease Business Unit of Shire. Earlier in his career, Sam worked at Endo Pharmaceuticals and GlaxoSmithKline. He received a Ph.D. in biochemistry from Louisiana State University and an MBA from Villanova University.

SAM RASTY, PHD

President and Chief Executive Officer

Headshot of Jonathan Thon by Katherine Taylor

JONATHAN THON, PHD

Co-founder and Chief Scientific Officer

Dr. Thon invented PBG’s platelet platform in his laboratory at Harvard Medical School, where he served as an assistant professor. He has published more than 30 peer-reviewed papers on the production and storage of platelets. He earned his Ph.D. in biochemistry and molecular biology from the University of British Columbia, Vancouver. He retains a position as lecturer at Harvard Medical School.

JONATHAN THON, PHD

Co-founder and Chief Scientific Officer

headshot of Sven Karlsson by Katherine Taylor

SVEN KARLSSON

Co-founder, Chief Operating Officer and Chief Business Officer

Sven Karlsson is the co-founder, chief operating officer and chief business officer of Platelet BioGenesis. He has more than a decade experience in business development and financial analysis. Prior to co-founding Platelet BioGenesis he worked as a merger and acquisition principal at J.P. Morgan, an analyst at a hedge fund, and as a venture capital investor. He earned his M.B.A. from the Stern School of Business at New York University.

SVEN KARLSSON, MBA

Co-founder, Chief Operating Officer and Chief Business Officer

Board of Directors

Headshot of Sam Rasty, PhD

SAM RASTY, PHD

President and Chief Executive Officer

Sam Rasty brings more than 20 years of experience in biopharma leadership in companies ranging from early-stage startups to global industry incumbents. Most recently, he served as chief operating officer at Homology Medicines, a leader in gene therapy and gene editing. Prior to Homology he was vice president and head of new products at the Rare Disease Business Unit of Shire. Earlier in his career, Sam worked at Endo Pharmaceuticals and GlaxoSmithKline. He received a Ph.D. in biochemistry from Louisiana State University and an MBA from Villanova University.

SAM RASTY, PHD

President and Chief Executive Officer

Headshot of Jonathan Thon by Katherine Taylor

JONATHAN THON, PHD

Co-founder and Chief Scientific Officer

Dr. Thon invented PBG’s platelet platform in his laboratory at Harvard Medical School, where he served as an assistant professor. He has published more than 30 peer-reviewed papers on the production and storage of platelets. He earned his Ph.D. in biochemistry and molecular biology from the University of British Columbia, Vancouver. He retains a position as lecturer at Harvard Medical School.

JONATHAN THON, PHD

Co-founder and Chief Scientific Officer

headshot of Sven Karlsson by Katherine Taylor

SVEN KARLSSON

Co-founder, Chief Operating Officer and Chief Business Officer

Sven Karlsson is the co-founder, chief operating officer and chief business officer of Platelet BioGenesis. He has more than a decade experience in business development and financial analysis. Prior to co-founding Platelet BioGenesis he worked as a merger and acquisition principal at J.P. Morgan, an analyst at a hedge fund, and as a venture capital investor. He earned his M.B.A. from the Stern School of Business at New York University.

SVEN KARLSSON, MBA

Co-founder, Chief Operating Officer and Chief Business Officer

headshot for Joseph Italiano, PhD

JOSEPH ITALIANO, PHD

Co-founder

Joseph Italiano, Ph.D. is an associate professor at Harvard Medical School, where he leads his own lab focused on platelet production. He is also assistant professor in the Department of Surgery at Children’s Hospital Boston. Dr. Italiano earned his Ph.D. in cell biology from Florida State University. He is a co-founder of Platelet BioGenesis and chairman of the company’s scientific advisory board.

JOSEPH ITALIANO, PHD

Co-founder

Headshot for Dr. Phil Reilly

PHILIP REILLY, MD, JD

Phil is a venture partner at Third Rock Ventures and has served as chief medical officer of Goldfinch Bio, co-founder of Fulcrum Therapeutics, co-founder and chief medical officer of Voyager Therapeutics, chief medical officer of Bluebird Bio, co-founder of Edimer, among other startup roles. He served as chairman and CEO of Interleukin Genetics. He earned his medical degree at the Yale School of Medicine.

PHILIP REILLY, MD, JD

Headshot for Mark McDade

MARK McDADE, MBA

Executive Chair

Mark is a managing partner of the Qiming U.S. Healthcare Fund. Previously, he served as chief operating officer of UCB Pharma, CEO of PDL BioPharma, CEO of Signature BioScience and COO of Boehringer Mannheim Therapeutics. He serves on the boards of FivePrime Therapeutics, Dermira Inc., and Aimmune Therapeutics. He received his M.B.A. from Harvard Business School.

MARK McDADE, MBA

Executive Chair

Photo of Richard Murray, PhD

RICHARD MURRAY, PHD

Richard Murray has served as Chief Executive Officer and President of Jounce Therapeutics, along with sitting on the Board of Directors, since July, 2014. He brings to Jounce more than two decades of biologics R&D leadership and experience moving product candidates through development to commercialization for both startup biotechnology and large pharmaceutical companies. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.

RICHARD MURRAY, PHD

Scientific Advisory Board

headshot for Joseph Italiano, PhD

JOSEPH ITALIANO, PHD

Co-founder

Joseph Italiano, Ph.D. is an associate professor at Harvard Medical School, where he leads his own lab focused on platelet production. He is also assistant professor in the Department of Surgery at Children’s Hospital Boston. Dr. Italiano earned his Ph.D. in cell biology from Florida State University. He is a co-founder of Platelet BioGenesis and chairman of the company’s scientific advisory board.

JOSEPH ITALIANO, PHD

Co-founder

Headshot of Dr. Ed Engleman

ED ENGLEMAN, MD

Ed Engleman, M.D., is medical director of the Stanford Blood Center and co-director of tumor immunology and immunotherapy at the Stanford Cancer Institute. Dr. Engleman’s research has focused on understanding the role of the cellular immune system in cancer and other diseases.

ED ENGLEMAN, MD

headshot of Bruce Zetter

BRUCE ZETTER, PHD

Bruce Zetter, Ph.D., is professor of cancer biology and surgery at Harvard Medical School, researcher at Boston Children’s Hospital and discoverer of the world’s first angiogenesis inhibitor.

BRUCE ZETTER, PHD

Headshot for Dr. Barry Coller

BARRY COLLER, MD

Barry Coller, M.D., professor, physician-in-chief and vice president for medical affairs at Rockefeller University. Coller helped develop abciximab, marketed as ReoPro, a platelet aggregation inhibitor widely used in patients implanted with stents.

BARRY COLLER, MD

Headshot for Cedric Ghevaert

CEDRIC GHEVAERT, PHD

Cedric Ghevaert, Ph.D., senior lecturer in transfusion medicine at the University of Cambridge and a consulting hematologist for the National Health Service Blood and Transplant division in the UK. Dr. Ghevaert has conducted groundbreaking first-in-man studies of blood cell survival and recovery.

CEDRIC GHEVAERT, PHD

headshot of Dr. Les Silberstein

LES SILBERSTEIN, MD

Les Silberstein, M.D., director of the Joint Program in Transfusion Medicine at Boston Children’s Hospital. Dr. Silberstein’s lab looks at signals that control hematopoietic stem and progenitor cells in bone marrow and their role in leukemia and other conditions.

LES SILBERSTEIN, MD